Literature DB >> 11122091

Characterization of osteoclast precursors in human blood.

V Shalhoub1, G Elliott, L Chiu, R Manoukian, M Kelley, N Hawkins, E Davy, G Shimamoto, J Beck, S A Kaufman, G Van, S Scully, M Qi, M Grisanti, C Dunstan, W J Boyle, D L Lacey.   

Abstract

Osteoclast precursors (OCPs) circulate in the mononuclear fraction of peripheral blood (PB), but their abundance and surface characteristics are unknown. Previous studies suggest that the receptor activator for NF-kappaB (RANK) on cytokine-treated OCPs in mouse bone marrow interacts with osteoprotegerin ligand (OPGL/TRANCE/RANKL/ODF) to initiate osteoclast differentiation. Hence, we used a fluorescent form of human OPGL (Hu-OPGL-F) to identify possible RANK-expressing OCPs in untreated peripheral blood mononuclear cells (PBMCs) using fluorescence-activated cell sorting analysis. Monocytes [CD14-phycoerythrin (PE) antibody (Ab) positive (+) cells, 10-15% of PBMCs] all (98-100%) co-labelled with Hu-OPGL-F (n > 18). T lymphocytes (CD3-PE Ab+ cells, 66% of PBMCs) did not bind Hu-OPGL-F; however, B cells (CD19-PE Ab+ cells, 9% of PBMCs) were also positive for Hu-OPGL-F. All Hu-OPGL-F+ monocytes also co-labelled with CD33, CD61, CD11b, CD38, CD45 and CD54 Abs, but not CD34 or CD56 Abs. Hu-OPGL-F binding was dose dependent and competed with excess Hu-OPGL. When Hu-OPGL-F+, CD14-PE Ab+, CD33-PE Ab+, Hu-OPGL-F+/CD14-PE Ab+ or Hu-OPGL-F+/CD33-PE Ab+ cells were cultured with OPGL (20 ng/ml) and colony-stimulating factor (CSF)-1 (25 ng/ml), OC-like cells readily developed. Thus, all freshly isolated monocytes demonstrate displaceable Hu-OPGL-F binding, suggesting the presence of RANK on OCPs in PB; also, OCPs within a purified PB monocyte population form osteoclast-like cells in the complete absence of other cell types in OPGL and CSF-1 containing medium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122091     DOI: 10.1046/j.1365-2141.2000.02379.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  36 in total

1.  Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes.

Authors:  Se Hwan Mun; Na Young Ko; Hyuk Soon Kim; Jie Wan Kim; Do Kyun Kim; A-Ram Kim; Seung Hyun Lee; Yong-Gil Kim; Chang Keun Lee; Seoung Hoon Lee; Bo Kyung Kim; Michael A Beaven; Young Mi Kim; Wahn Soo Choi
Journal:  Cell Mol Life Sci       Date:  2010-06-08       Impact factor: 9.261

2.  Interactions between the immune system and bone.

Authors:  Patrizia D'Amelio; Giorgia Fornelli; Ilaria Roato; Giovanni Carlo Isaia
Journal:  World J Orthop       Date:  2011-03-18

3.  Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.

Authors:  J Costa-Rodrigues; A Fernandes; M H Fernandes
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

4.  Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis.

Authors:  Guillaume Mabilleau; Daniel Chappard; Afsie Sabokbar
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

5.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

Authors:  Sutada Lotinun; Riku Kiviranta; Takuma Matsubara; Jorge A Alzate; Lynn Neff; Anja Lüth; Ilpo Koskivirta; Burkhard Kleuser; Jean Vacher; Eero Vuorio; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

6.  Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion.

Authors:  Nicola Dalbeth; Bregina Pool; Timothy Smith; Karen E Callon; Maria Lobo; William J Taylor; Peter B Jones; Jillian Cornish; Fiona M McQueen
Journal:  Arthritis Res Ther       Date:  2010-08-26       Impact factor: 5.156

7.  In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes.

Authors:  Francesca Salamanna; Melania Maglio; Gianluca Giavaresi; Stefania Pagani; Roberto Giardino; Milena Fini
Journal:  Age (Dordr)       Date:  2015-08-07

8.  Alendronate reduces osteoclast precursors in osteoporosis.

Authors:  P D'Amelio; A Grimaldi; M A Cristofaro; M Ravazzoli; P A Molinatti; G P Pescarmona; G C Isaia
Journal:  Osteoporos Int       Date:  2009-12-01       Impact factor: 4.507

9.  The proliferative human monocyte subpopulation contains osteoclast precursors.

Authors:  Roya Lari; Peter D Kitchener; John A Hamilton
Journal:  Arthritis Res Ther       Date:  2009-02-17       Impact factor: 5.156

10.  Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.

Authors:  Guillaume Mabilleau; Afsie Sabokbar
Journal:  PLoS One       Date:  2009-01-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.